Role of microvascular dysfunction in left ventricular dysfunction in type 2 diabetes mellitus

2021 ◽  
Vol 35 (5) ◽  
pp. 107907
Author(s):  
Amera Halabi ◽  
Mark Nolan ◽  
Elizabeth Potter ◽  
Leah Wright ◽  
Atef Asham ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Microvascular Dysfunction ◽  
Left Ventricular

scholarly journals Subclinical left ventricular dysfunction and 10-year outcomes in type 2 diabetes mellitus

2015 ◽  
Vol 24 ◽  
pp. S364
Author(s):  
D. Holland ◽  
T. Marwick ◽  
B. Haluska ◽  
R. Leano ◽  
M. Hordern ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular

Left ventricular dysfunction in hypertensive patients with Type 2 diabetes mellitus

2005 ◽  
Vol 22 (9) ◽  
pp. 1218-1225 ◽  
Author(s):  
N. H. Andersen ◽  
S. H. Poulsen ◽  
P. L. Poulsen ◽  
S. T. Knudsen ◽  
K. Helleberg ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Hypertensive Patients

scholarly journals Left ventricular dysfunction in patients with type 2 diabetes mellitus

2019 ◽  
Vol 7 (1) ◽  
pp. 27
Author(s):  
Manish Chandey ◽  
Robin Kamboj ◽  
Tejinder Sikri ◽  
Nivenjit Kaur
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diastolic Dysfunction ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Lv Diastolic Dysfunction

Background: Diabetes mellitus (DM) is on the increase globally. Cardiovascular complications, such as left ventricular dysfunction is a major cause of death in patients with type II DM. Prior to the development of symptomatic heart failure, subclinical left ventricular dysfunction (systolic and diastolic) may exist for some time. Aim of this study is to find out abnormalities in left ventricular function in patients of type 2 diabetes mellitus with help of 2D Colour Doppler Echocardiography. To find its correlation with glycemic control on the basis of glycosylated haemoglobin (Hba1c).Methods: Total 100 Patients of type 2 Diabetes Mellitus of duration more than 10 years of both sexes were included in the cross-sectional study conducted from Jan 2018 to Aug 2019.All the patients were assessed through clinical examination and 2-D echocardiography and control of diabetes determined on the basis of HbA1c.Results: Study consisted of 100 patients with type 2 DM, 55(55%) were females and 45(45%) males. Majority of patients were in the age group of 4th to 6th decade of life.  Diastolic dysfunction was present in 81(81%) patients. systolic dysfunction was present in 14(14%) patients. There was a linear increase in prevalence of diastolic dysfunction with increasing age, increased FPG, increased BMI. There was also significant correlation between LV diastolic dysfunction (LVDD) and LA size. While no statistical correlation found between gender, duration of diabetes, HbA1c with diastolic and systolic dysfunction.Conclusions: LV diastolic dysfunction is an early manifestation of diabetic cardiomyopathy. LVDD contributes significantly to morbidity of congestive heart failure in diabetic patients. Echocardiography is a very useful non-invasive tool in detecting LVDD and systolic dysfunction in type 2 DM patients. 

scholarly journals Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Type 2 Diabetes Mellitus

2021 ◽  
Author(s):  
Chun-Ka WONG ◽  
Duo HUANG ◽  
Mi ZHOU ◽  
Yee-Man LAU ◽  
Wing-Hon LAI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Opportunistic Screening ◽  
Ckd Stage ◽  
Artery Disease

Abstract BACKGROUND Prevention of heart failure (HF) has been recognized as an urgent public health need. International guidelines recommend natriuretic peptide biomarker-based screening for patients at high HF risk to allow early detection and intervention to delay HF progression and mortality. Little has been reported the incorporation of screening procedure to existing clinical practice. The objective of the study was to describe the opportunistic screening of left ventricular dysfunction in patients with type 2 diabetes mellitus (DM). METHOD This was a prospective screening study at the DM complication screening center. RESULTS Between 2018 and 2019, 1,132 consecutive DM patients with no prior history of HF or atrial fibrillation (AF) attending regular complication screening were invited to participate. Of these, 89 patients refused or failed to complete the screening. The final analysis included 1,043 patients (age: 63.7±12.4 years; male: 56.3%). The mean HbA1c was 7.25±1.34%. There were 81.8% patients with concomitant hypertension, 31.1% with coronary artery disease, 8.0% with previous stroke, and 5.5% with peripheral artery disease. Furthermore, 45.7% patients had diabetic retinopathy, 33.6% had peripheral neuropathy, and 30.7% had chronic kidney disease (CKD) stage 3-5. At the screening session, 43 patients (4.1%) had an elevated NT-proBNP concentration above the age-specific diagnostic thresholds for HF, and 43 patients (4.1%) had newly detected AF. The prevalence of elevated NT-proBNP concentration increased with age from 0.85% in patients aged <50 years to 7.14% in those aged 70-79 years and worsening kidney function from 0.43% in patients with CKD stage 1 to 42.86% in CKD stage 5. In multivariate logistic regression, male gender (OR: 3.67 (1.47-9.16), p =0.005*), prior stroke (OR: 3.26 (1.38-7.69), p= 0.007*), CKD ( p <0.001*), and newly detected AF (OR: 7.02 (2.65-18.57), p <0.001*) were significantly associated with elevated NT-proBNP concentration. Amongst patients with elevated NT-proBNP concentration, their mean left ventricular ejection fraction (LVEF) was 51.4 ± 14.7%, and 45% patients had a LVEF <50%. CONCLUSION Both NT-proBNP and ECG screening could be easily implemented. Our findings demonstrate systemic screening allows detection of early phase HF and asymptomatic AF in patients with DM, thereby facilitating the implementation of preventive measure to improve the long-term outcomes.

Sign in / Sign up

Export Citation Format

Share Document